Therapeutics / RNAi / BioTech / Biotech / Pharmaceuticals / Pharmaceutical / Drug / Drugs / Gene / Protein / Genes / Research / Boston blog main / Boston top stories / Europe / Europe blog main / Europe top stories / National blog main / National top stories / Alexion Pharmaceuticals / Alnylam Pharmaceuticals / Arbutus Biopharma / Arrowhead Pharmaceuticals / AstraZeneca / Beta-Thalassemia / cardiometabolic disorders / Cardiovascular Disease / deals / Dicerna Pharmaceuticals / hereditary transthyretin amyloidosis / Iain Ross / John Strafford / Life Sciences / Mallinckrodt Pharmaceuticals / myelodysplastic syndrome / Regeneron Pharmaceuticals / Respiratory Disease / RNA Interference / Silence Therapeutics / Takeda Pharmaceutical

AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics

Posted On: Mar 25, 2020   |   Posted By: Xconomy

AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics

After years of research, technology for silencing a gene-stopping it from producing a disease-causing protein-has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs. According to deal terms announced Wednesday, AstraZeneca will pay London-based Silence $60 million up front. The pharmaceutical giant will also make a $20 million equity investment in its new partner. The companies initially aim to work on five targets over the next three years. AstraZeneca has the option to expand the pact to another five...

Continue reading ...